Rebound weight gain

Rebound weight gain is the regain that typically follows stopping a GLP-1 medication. It’s the most consistently documented — and most under-discussed — part of the treatment picture.

What the studies show

• STEP 1 extension (Wilding et al., 2022): one year after stopping semaglutide 2.4 mg, participants had regained roughly two-thirds of the weight they’d lost. Cardiometabolic improvements largely reverted too.
• SURMOUNT-4 (Aronne et al., 2024): after 36 weeks on tirzepatide, participants switched to placebo regained about 14% of body weight over the following year, while those who stayed on continued to lose.

Why it happens

The medication doesn’t reset appetite biology permanently — it suppresses it while present. Stop the drug and appetite signals, food noise, and the body’s weight-defense mechanisms come back, usually within weeks. This isn’t a personal failure any more than blood pressure rising after stopping medication is; it’s pharmacology.

What this means practically

Obesity medicine increasingly treats GLP-1 therapy as long-term management of a chronic condition rather than a short course. For people who do stop — by choice, cost, supply, or side effects — the transition period is where habits, protein intake, strength training, and honest tracking matter most, and where a recorded baseline of your own patterns (what maintenance actually looked like for you) becomes genuinely valuable. Any decision to stop or taper belongs in a conversation with your prescriber.